Machine learning diagnosis by immunoglobulin<i>N</i>‐glycan signatures for precision diagnosis of urological diseases
Hiromichi Iwamura(Hirosaki University), Tohru Yoneyama(Hirosaki University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Daisuke Noro(Hirosaki University), Yuki Tobisawa(Hirosaki University), Naoki Fujita(Yamaguchi University), Shigeyuki Nakaji(Hirosaki University), Takuma Narita(Hirosaki University), Shintaro Narita(Akita University), Shinichi Yamashita, Ken Itoh(Hirosaki University), Kei Mizuno(Dana-Farber Cancer Institute), Ikuko Kakizaki(Hirosaki University), Chikara Οhyama(Hirosaki University), Shusuke Akamatsu(Kyoto University), Toshihiko Sakurai(Sojo University), Hirotake Kodama(Hirosaki University)
Cited by 16
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Association of a novel long non‐coding RNA in <i>8q24</i> with prostate cancer susceptibility
|Cancer Science|2010|286
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253
Role of phase 2 enzyme induction in chemoprotection by dithiolethiones
|Mutation research. Fundamental and molecular mechanisms of mutagenesis|2001|244